![]() |
| Professor Anton Peleg with Dr Jhih-Hang Jiang and Hsin-Hui Shen. |
by Dr Jhih-Hang Jiang & Grace Williams, Monash Biomedicine Discovery Institute
A multidisciplinary study led by Monash scientists has shown how one of the most important human superbugs, Staphylococcus aureus, can evade last-line antibiotics and the host immune system during a life-threatening infection. The findings uncover a novel strategy used by S. aureus (Golden staph), whereby it rapidly adapts its bacterial membrane to circumvent antibiotic and immune killing. These findings potentially point to a new therapeutic target for this significant bacterial pathogen.
S. aureus can cause serious infection of almost any human tissue and mortality from treated infections is up to 35 per cent. It is estimated that around 7000 cases of S. aureus bloodstream infections occur in Australia each year, and about 25 per cent are caused by methicillin-resistant S. aureus (MRSA). Without the ability to use the antibiotic methicillin, treatment of MRSA infection increasingly relies on last-line antibiotics. The World Health Organization (WHO) has listed MRSA as a ‘high-priority’ pathogen that urgently requires the development of new antimicrobial agents.



